tag:blogger.com,1999:blog-9226230.post111159460790317419..comments2023-10-20T05:43:46.254-07:00Comments on All Allan: DNDNUnknownnoreply@blogger.comBlogger2125tag:blogger.com,1999:blog-9226230.post-1115485658136294302005-05-07T10:07:00.000-07:002005-05-07T10:07:00.000-07:00Hi, Ross, Besides the chart, do you dislike dndn b...Hi, Ross, <BR/><BR/>Besides the chart, do you dislike dndn based on the prospects of their drug, Provenge (an active immunotherapy for prostate cancer)? <BR/><BR/>Also, besides the charts, are there any biotech companies with products/technologies that you do like?<BR/><BR/>Thanks, Ileneilenehttps://www.blogger.com/profile/00859456411740769913noreply@blogger.comtag:blogger.com,1999:blog-9226230.post-1112448783091503642005-04-02T06:33:00.000-07:002005-04-02T06:33:00.000-07:00Allan,For what it is worth, DNDN looks like a dog ...Allan,<BR/><BR/>For what it is worth, DNDN looks like a dog with fleas. I hardly call a few thousand dollar investments significant, rather, it was probably a knee jerk reaction to the continued bad news. The CFO by the way, exercised options at 91 cents per share on 3/18. <BR/><BR/>Crappy chart, crappy selling, crappy effort by the insiders and most important, crappy company. Only the 2P's (plumbers and proctologists) make money in crap.<BR/><BR/>$3.21 a share in cash? Does this include include their crappy inventory too?<BR/><BR/>How can you short term trade this one? The old Peter Lynch about catching a falling knife applies here.<BR/><BR/>You have had many other good picks to tell us about. This may not be your best.<BR/><BR/>Warm Regards,<BR/><BR/>RossAnonymousnoreply@blogger.com